154 related articles for article (PubMed ID: 38243657)
1. DEAD-box helicase 1 inhibited CD8
Liu J; Yang T; Luo Y; Ma Z; Yu Z; Zhang L; Liu G; Wen J; Lu G; Zhang G; Zhao Y; Luo W; Li Y; Yang N; Zhou J; Lu Y; Chen S; Zeng X
Cancer Sci; 2024 Mar; 115(3):763-776. PubMed ID: 38243657
[TBL] [Abstract][Full Text] [Related]
2. Disruption of SIRT7 Increases the Efficacy of Checkpoint Inhibitor via MEF2D Regulation of Programmed Cell Death 1 Ligand 1 in Hepatocellular Carcinoma Cells.
Xiang J; Zhang N; Sun H; Su L; Zhang C; Xu H; Feng J; Wang M; Chen J; Liu L; Shan J; Shen J; Yang Z; Wang G; Zhou H; Prieto J; Ávila MA; Liu C; Qian C
Gastroenterology; 2020 Feb; 158(3):664-678.e24. PubMed ID: 31678303
[TBL] [Abstract][Full Text] [Related]
3. Sensitizing tumors to anti-PD-1 therapy by promoting NK and CD8+ T cells via pharmacological activation of FOXO3.
Chung YM; Khan PP; Wang H; Tsai WB; Qiao Y; Yu B; Larrick JW; Hu MC
J Immunother Cancer; 2021 Dec; 9(12):. PubMed ID: 34887262
[TBL] [Abstract][Full Text] [Related]
4. Relationship Between PD-L1 Expression and CD8+ T-cell Immune Responses in Hepatocellular Carcinoma.
Huang CY; Wang Y; Luo GY; Han F; Li YQ; Zhou ZG; Xu GL
J Immunother; 2017; 40(9):323-333. PubMed ID: 29028787
[TBL] [Abstract][Full Text] [Related]
5. Role of regulatory T cells and checkpoint inhibition in hepatocellular carcinoma.
Langhans B; Nischalke HD; Krämer B; Dold L; Lutz P; Mohr R; Vogt A; Toma M; Eis-Hübinger AM; Nattermann J; Strassburg CP; Gonzalez-Carmona MA; Spengler U
Cancer Immunol Immunother; 2019 Dec; 68(12):2055-2066. PubMed ID: 31724091
[TBL] [Abstract][Full Text] [Related]
6. Glycolytic activation of peritumoral monocytes fosters immune privilege via the PFKFB3-PD-L1 axis in human hepatocellular carcinoma.
Chen DP; Ning WR; Jiang ZZ; Peng ZP; Zhu LY; Zhuang SM; Kuang DM; Zheng L; Wu Y
J Hepatol; 2019 Aug; 71(2):333-343. PubMed ID: 31071366
[TBL] [Abstract][Full Text] [Related]
7. Antibodies Against Immune Checkpoint Molecules Restore Functions of Tumor-Infiltrating T Cells in Hepatocellular Carcinomas.
Zhou G; Sprengers D; Boor PPC; Doukas M; Schutz H; Mancham S; Pedroza-Gonzalez A; Polak WG; de Jonge J; Gaspersz M; Dong H; Thielemans K; Pan Q; IJzermans JNM; Bruno MJ; Kwekkeboom J
Gastroenterology; 2017 Oct; 153(4):1107-1119.e10. PubMed ID: 28648905
[TBL] [Abstract][Full Text] [Related]
8. Interferon regulatory factor 1 (IRF-1) and IRF-2 regulate PD-L1 expression in hepatocellular carcinoma (HCC) cells.
Yan Y; Zheng L; Du Q; Yan B; Geller DA
Cancer Immunol Immunother; 2020 Sep; 69(9):1891-1903. PubMed ID: 32377817
[TBL] [Abstract][Full Text] [Related]
9. Aucubin enhances the antitumor activity of cisplatin through the inhibition of PD-L1 expression in hepatocellular carcinoma.
Gao ZX; Zhang ZS; Qin J; Zhang MZ; Cao JL; Li YY; Wang MQ; Hou LL; Fang D; Xie SQ
Phytomedicine; 2023 Apr; 112():154715. PubMed ID: 36821999
[TBL] [Abstract][Full Text] [Related]
10. Disruption of tumour-associated macrophage trafficking by the osteopontin-induced colony-stimulating factor-1 signalling sensitises hepatocellular carcinoma to anti-PD-L1 blockade.
Zhu Y; Yang J; Xu D; Gao XM; Zhang Z; Hsu JL; Li CW; Lim SO; Sheng YY; Zhang Y; Li JH; Luo Q; Zheng Y; Zhao Y; Lu L; Jia HL; Hung MC; Dong QZ; Qin LX
Gut; 2019 Sep; 68(9):1653-1666. PubMed ID: 30902885
[TBL] [Abstract][Full Text] [Related]
11. Radiation Therapy Promotes Hepatocellular Carcinoma Immune Cloaking via PD-L1 Upregulation Induced by cGAS-STING Activation.
Du SS; Chen GW; Yang P; Chen YX; Hu Y; Zhao QQ; Zhang Y; Liu R; Zheng DX; Zhou J; Fan J; Zeng ZC
Int J Radiat Oncol Biol Phys; 2022 Apr; 112(5):1243-1255. PubMed ID: 34986380
[TBL] [Abstract][Full Text] [Related]
12. Kupffer cell suppression of CD8+ T cells in human hepatocellular carcinoma is mediated by B7-H1/programmed death-1 interactions.
Wu K; Kryczek I; Chen L; Zou W; Welling TH
Cancer Res; 2009 Oct; 69(20):8067-75. PubMed ID: 19826049
[TBL] [Abstract][Full Text] [Related]
13. Sorafenib suppresses radioresistance and synergizes radiotherapy-mediated CD8
Cheng CC; Ho AS; Peng CL; Chang J; Sie ZL; Wang CL; Chen YL; Chen CY
Int Immunopharmacol; 2022 Nov; 112():109110. PubMed ID: 36037651
[TBL] [Abstract][Full Text] [Related]
14. Abrine, an IDO1 inhibitor, suppresses the immune escape and enhances the immunotherapy of anti-PD-1 antibody in hepatocellular carcinoma.
Liang X; Gao H; Xiao J; Han S; He J; Yuan R; Yang S; Yao C
Front Immunol; 2023; 14():1185985. PubMed ID: 37334368
[TBL] [Abstract][Full Text] [Related]
15. Dihydroartemisinin broke the tumor immunosuppressive microenvironment by inhibiting YAP1 expression to enhance anti-PD-1 efficacy.
Peng Q; Li S; Shi X; Guo Y; Hao L; Zhang Z; Ji J; Zhao Y; Li C; Xue Y; Liu Y
Phytother Res; 2023 May; 37(5):1740-1753. PubMed ID: 36576358
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of T-cell-mediated immune response via the PD-1/ PD-L1 axis in cholangiocarcinoma cells.
Suriyo T; Fuangthong M; Artpradit C; Ungtrakul T; Sricharunrat T; Taha F; Satayavivad J
Eur J Pharmacol; 2021 Apr; 897():173960. PubMed ID: 33617828
[TBL] [Abstract][Full Text] [Related]
17. EZH2 negatively regulates PD-L1 expression in hepatocellular carcinoma.
Xiao G; Jin LL; Liu CQ; Wang YC; Meng YM; Zhou ZG; Chen J; Yu XJ; Zhang YJ; Xu J; Zheng L
J Immunother Cancer; 2019 Nov; 7(1):300. PubMed ID: 31727135
[TBL] [Abstract][Full Text] [Related]
18. Huaier improves the efficacy of anti-PD-L1 Ab in the treatment of hepatocellular carcinoma by regulating tumor immune microenvironment.
Li H; You J; Wei Y; Zheng L; Yang J; Xu J; Li Y; Li Z; Yang X; Yi C
Phytomedicine; 2024 Jan; 123():155189. PubMed ID: 37984124
[TBL] [Abstract][Full Text] [Related]
19. LAIR1-mediated resistance of hepatocellular carcinoma cells to T cells through a GSK-3β/β-catenin/MYC/PD-L1 pathway.
Pan B; Ke X; Qiu J; Ye D; Zhang Z; Zhang X; Luo Y; Yao Y; Wu X; Wang X; Tang N
Cell Signal; 2024 Mar; 115():111039. PubMed ID: 38199599
[TBL] [Abstract][Full Text] [Related]
20. Interferon Gamma-Induced Interferon Regulatory Factor 1 Activates Transcription of HHLA2 and Induces Immune Escape of Hepatocellular Carcinoma Cells.
Wang R; Guo H; Tang X; Zhang T; Liu Y; Zhang C; Yu H; Li Y
Inflammation; 2022 Feb; 45(1):308-330. PubMed ID: 34536158
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
